Program Description
Patients with heart failure (HF) can be divided into 2 broad classifications: heart failure with preserved ejection fraction and heart failure with reduced ejection fraction (HFrEF). Most cases of HFrEF are caused by ischemic heart disease or hypertension, but in around 20% to 30% of patients, the cause is not identified. The complex nature of HF is further exacerbated by the frequent occurrence of cardiac and noncardiac comorbidities and polypharmacy experienced by the majority of patients with HF. Pharmacists are valuable members of the multidisciplinary team approach to long-term management of health-related impacts of chronic worsening of HFrEF to improve patient quality of life. This activity will explore the potential biomarkers for HF that contribute to clinical diagnosis and prediction of prognosis for patients. Newly approved and emerging therapies for the treatment of chronic or worsening HF will be reviewed to assist pharmacists with clinical decision making for the initiation, titration, and monitoring of HF therapies for patients.
Target audience: Health-system and retail pharmacists
Type of activity: Application
Release date: June 28, 2022
Expiration date: August 28, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the clinical burden of heart failure (HF) and the emerging role of biomarkers
- Analyze the most up-to-date efficacy and safety data of soluble guanylate cyclase (sGC) stimulators and cardiac myosin activators in the treatment of chronic worsening HF with reduced ejection fraction (HFrEF)
- Illustrate the role of the pharmacist in making clinical recommendations and managing patients with chronic worsening HFrEF
Stormi Gale, PharmD, BCPS, BCCP
Clinical Pharmacist, Cardiology Subject Matter Expert
Novant Health Matthews Medical Center
Matthews, North Carolina
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-244-L01-P. The activity is available for CE credit through August 28, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Stormi Gale, PharmD, BCPS, BCCP, has the following financial relationships with commercial interests to disclose:
Consultant: Kiniksa, Pharmacosmos
The following contributors have no relevant financial relationships with commercial interests to disclose:
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa-Buszka, PharmD, BCPS; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Pharmacy Times® Editorial Staff—Davy James
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms